NEW YORK, July 29, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (Nasdaq:OVAS) securities between February 25, 2013 and September 10, 2013.
Click here to learn about the case: http://docs.wongesq.com/OVAS-Info-Request-Form-319. There is no cost or obligation to you.
The complaint alleges that defendants made materially false and misleading statements regarding the Company's business and operations. In particular, OvaScience represented to investors and the Food and Drug Administration that its fertility treatment AUGMENT would likely qualify for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure.
If you suffered a loss in OvaScience you have until August 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/OVAS-Info-Request-Form-319.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: firstname.lastname@example.orgSource:The Law Offices of Vincent Wong